PubMed | Anderson Cancer Center Hospital, University of Barcelona, Health Research Institute of Santiago IDIS, Institute Dinvestigacions Biomediques Of Bellvitge Idibell and 5 more.
Type: | Journal: International journal of cancer | Year: 2016
In developed countries, endometrial carcinoma is the most common cancer that affects the female genital tract. Endometrial carcinoma is divided into two main histological types, type I or endometrioid and type II or non-endometrioid, each of which have characteristic, although not exclusive, molecular alterations and mutational profiles. Nevertheless, information about the implication and relevance of some of these genes in this disease is lacking. We sought here to identify new recurrently mutated genes in endometrioid cancers that play a role in tumourigenesis and that influence the clinical outcome. We focused on low grade, non-ultramutated tumours as these tumours have a worse prognosis than the ultramutated POLE-positive endometrioid endometrial carcinomas. We performed exome-sequencing of 11 endometrioid endometrial carcinomas with matched normal tissue and subsequently validated 15 candidate genes in 76 samples. For the first time, we show that mutations in chromatin remodelling related genes (KMT2D, KMT2C, SETD1B and BCOR) and in DNA repair related genes (BRCA1, BRCA2, RAD50 and CHD4) are frequent in this subtype of endometrial cancer. The alterations to these genes occurred with frequencies ranging from 35.5% for KMT2D to 10.5% for BRCA1 and BCOR, with some showing a tendency towards co-occurrence (RAD50-KMT2D and RAD50-SETD1B). All of these genes harboured specific mutational hotspots. In addition, the mutational status of KMT2C, KMT2D and SETD1B helps to predict the degree of myometrial invasion, a critical prognostic feature. These results highlight the possible implication of these genes in this disease, creating opportunities for new therapeutic approaches. This article is protected by copyright. All rights reserved.